Cargando…
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramuciru...
Autores principales: | Rimassa, Lorenza, Wörns, Marcus‐Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496898/ https://www.ncbi.nlm.nih.gov/pubmed/32432830 http://dx.doi.org/10.1111/liv.14533 |
Ejemplares similares
-
Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019) -
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023) -
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
por: Trojan, Jörg, et al.
Publicado: (2016) -
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
por: Cammarota, Antonella, et al.
Publicado: (2022) -
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)